Pfizer–Trump $70B Deal: Red Flag Checklist for Corporate Betrayal or Public Benefit. Trump’s new $70 billion Pfizer deal raises big questions. Who really wins—patients or Big Pharma? Use this red flag checklist to spot hidden risks in pharma–government agreements.
From the Pen or keyboard of John Rappoport:
The new Pfizer Trump deal just pledged—how horrible is it?
First of all, the devil is in the details, and a lot of details aren’t yet available.
Putting that aside, we DO SEE Trump going back to his old criminal friend, Pfizer CEO Albert Bourla, to make a deal. “Albert, great guy, great businessman.” There they are, just as they were at launch of the murderous Warp Speed.
And Kennedy is in “stand-by mode.” Watching the two titans do their $$$ tap dance.
Pfizer is promising to cut prices for some of its drugs, for Medicaid. Also, it will spend $70 billion to build research labs and manufacturing plants in the US, not in foreign countries.
Trump, in return, will exempt Pfizer from tariffs applied to materials Pfizer has shipped to the US from foreign countries.
Depending on how much those tariffs amount to over the next several years, Pfizer will essentially be “repaid” some or possibly all of its $70 billion investment.
Right now, it looks like “some.” Still, that’s a good deal for Pfizer. It gets investment $$ back. And the profits it makes from the labs and manufacturing plants in the US are very nice for Pfizer, too.
The whole deal is a bonanza for Pfizer, a vast criminal corporate enterprise. Brought to us by Trump.
Here’s a further kicker. Some of the Pfizer labs and manufacturing facilities will be researching and producing killer COVID vaccines and other killer RNA vaccines. BOOM.
A present to Bourla and Pfizer from Trump. With Kennedy standing by. Watching....
Let\s create a checklist for these types of deals.
🔎 Red Flag Checklist for Pharma–Government Deals
1. Transparency of Terms
✅ Delivering: Full text of the agreement is public, with clear lists of which drugs, price changes, timelines, and conditions apply.
🚩 Betrayal: Only press releases and soundbites exist; details are buried in confidential memoranda, making independent scrutiny impossible.
2. Scope of Price Cuts
✅ Price reductions apply broadly to most high-use drugs (not just a handful of low-volume products).
🚩 Reductions are narrowly targeted (e.g., 2–3 drugs, or Medicaid only) while headline language suggests massive reform.
3. Net vs. List Price
✅ Net price after rebates, discounts, and middleman markups actually drops for patients at point of sale.
🚩 “Cuts” only apply to list price, while net cost (what insurers, patients, or taxpayers pay) remains high.
4. Tariff/Tax Trade-Offs
✅ Government concessions (tariff exemptions, tax breaks) are less than or equal to what patients actually save.
🚩 Pharma receives tariff relief or tax subsidies larger than the total price cuts delivered — meaning the “savings” are just shifted from consumers to taxpayers.
5. Investment Promises
✅ Domestic investment (e.g., $70B labs/factories) is independently verified, with penalties if goals aren’t met.
🚩 Announced investments are unenforceable, or can be clawed back through loopholes, rebates, or tariff offsets.
6. Oversight and Enforcement
✅ Independent auditors, watchdogs, or public reporting required at regular intervals.
🚩 Enforcement depends on pharma self-reporting, with no meaningful penalties for noncompliance.
7. Product Lines Included
✅ Essential medicines, chronic illness drugs, and high-cost treatments are covered.
🚩 Discounts are concentrated in marginal or older products, while blockbuster or new drugs (esp. RNA/vaccine pipelines) remain untouched.
8. Time Horizon
✅ Changes are permanent or locked in for at least 5–10 years.
🚩 Concessions expire in 2–3 years (after the political optics are won), with pharma free to raise prices again.
9. Public Benefit vs. Corporate Leverage
✅ The deal reduces dependence on a single company and opens space for competition.
🚩 It entrenches a dominant player (Pfizer), granting it regulatory or tariff privileges that competitors can’t match.
10. Past Behavior Check
✅ The company has a track record of honoring past commitments in similar deals.
🚩 The company has repeatedly been fined for fraud, misreporting, or regulatory abuse (Pfizer has one of the biggest pharma settlement histories).
⚖️ Applying It to the Pfizer–Trump Deal
Based on what’s public so far:
🚩 Transparency: Low — only selective details have been released.
🚩 Scope: Likely narrow (some Medicaid drugs, some consumer discounts).
🚩 Tariff Trade-Offs: High risk Pfizer is made whole.
🚩 Oversight: Not yet clear.
🚩 Product Lines: Includes RNA vaccine infrastructure (a concern for critics).
🚩 Time Horizon: Only 3 years of tariff exemptions.
🚩 Past Behavior: Pfizer’s settlement history is extensive.
So right now, this checklist suggests the risk of betrayal is higher than the likelihood of genuine systemic reform — though some modest consumer gains (cheaper Medicaid drugs, job creation) may materialize.
sharing is caring
Comments
Post a Comment